Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug;66(8):611-6.
doi: 10.1007/s00105-015-3644-7.

[Lupus erythematosus]

[Article in German]
Affiliations
Review

[Lupus erythematosus]

[Article in German]
C Günther et al. Hautarzt. 2015 Aug.

Abstract

Background: Lupus erythematosus is an autoimmune disease with a broad spectrum of cutaneous manifestations. The pathogenesis of lupus is based on a loss of tolerance against self antigens and can be mediated by defects in apoptosis, defects in eliminating cellular remnants and increased activation of the innate as well as the adaptive immune system. The increased activation of the innate immune system can be mediated by sensing of endogenous or exogenous nucleic acids, genetic variants in the components of the receptor cascade or disturbances in restriction of self nucleic acids. The inflammatory milieu is characterized by type I interferon expression and autoantibody production. The main trigger factors of the disease are sun exposure and viral infections.

Treatment: Lupus erythematosus is effectively treated by glucocorticosteroids. Approved alternatives for long-term treatment are antimalarial agents and the B-cell inhibitor belimumab for patients with systemic lupus erythematosus.

Conclusion: Future studies should more intensely analyse the effect of novel therapies on cutaneous manifestations to allow early detection of cutaneous lupus. Furthermore novel therapeutic strategies which specifically target the responsible pathogenetic mechanisms of the individual subtypes of lupus erythematosus are needed to improve the therapeutic success for this heterogeneous patient population.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arthritis Rheum. 2013 Apr;65(4):1011-21 - PubMed
    1. Cell. 2008 Aug 22;134(4):587-98 - PubMed
    1. J Am Acad Dermatol. 2013 Dec;69(6):e303-5 - PubMed
    1. J Am Acad Dermatol. 2014 Mar;70(3):583-4 - PubMed
    1. Nat Genet. 2011 Oct 23;43(12):1186-8 - PubMed

MeSH terms

LinkOut - more resources